UK markets close in 4 hours 49 minutes
  • FTSE 100

    7,199.25
    +29.97 (+0.42%)
     
  • FTSE 250

    18,720.81
    +54.03 (+0.29%)
     
  • AIM

    876.16
    -0.06 (-0.01%)
     
  • GBP/EUR

    1.1540
    -0.0071 (-0.61%)
     
  • GBP/USD

    1.2076
    -0.0100 (-0.82%)
     
  • BTC-GBP

    16,064.91
    +188.63 (+1.19%)
     
  • CMC Crypto 200

    417.50
    -13.97 (-3.24%)
     
  • S&P 500

    3,785.38
    -33.45 (-0.88%)
     
  • DOW

    30,775.43
    -253.88 (-0.82%)
     
  • CRUDE OIL

    107.54
    +1.78 (+1.68%)
     
  • GOLD FUTURES

    1,790.70
    -16.60 (-0.92%)
     
  • NIKKEI 225

    25,935.62
    -457.42 (-1.73%)
     
  • HANG SENG

    21,859.79
    -137.10 (-0.62%)
     
  • DAX

    12,838.24
    +54.47 (+0.43%)
     
  • CAC 40

    5,951.18
    +28.32 (+0.48%)
     

Immunicum AB: Immunicum to Participate in Upcoming Conferences

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
Immunicum AB
Immunicum AB

Immunicum AB (publ; IMMU.ST), a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, today announced its participation in the following upcoming conferences:


Redeye Growth Day 2022

June 2, 2022

Immunicum CEO Erik Manting will participate in an on-site Q&A session on June 2, at 08:55 am CET. Further details including the on-demand corporate presentation are available via:
https://redeye.ifairs.com/#/booth?id=687


BioStock Life Science Spring Summit

June 8-9, 2022

Immunicum CEO Erik Manting will present on June 9, at 10:20 am CET.

https://www.biostock.se/en/2022/04/biostock-life-science-spring-summit-june-8-9/


European Hematology Association (EHA) 2022 Congress

June 9-17, 2022

https://ehaweb.org/congress/eha2022-hybrid/eha2022-congress/


BIO International Convention

June 13-16, 2022

https://www.bio.org/events/bio-international-convention


FOR MORE INFORMATION, PLEASE CONTACT:

Erik Manting

Chief Executive Officer

E-mail: ir@immunicum.com


INVESTOR RELATIONS

Julie Seidel

Stern Investor Relations

Telefon: +1 212-362-1200

E-mail: julie.seidel@sternir.com


MEDIA RELATIONS

Mario Brkulj

Valency Communications

Telephone: +49 160 9352 9951

E-mail: mbrkulj@valencycomms.eu


ABOUT IMMUNICUM AB (PUBL)
Immunicum is a biopharmaceutical company focused on therapies addressing tumor recurrence and hard-to-treat established tumors, two key challenges in oncology. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based therapies for blood-borne and solid tumors. Based in Sweden and the Netherlands, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com

Attachment


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting